Rexaceract Shows 12-Month Motor Stability in Parkinson's, Phase 2 Set for 1Q27
GANX is trading near its 52-week low of $1.53 (14% above the low).
Summary
Gain Therapeutics presented 12-month open-label extension data for rexaceract in Parkinson's disease, showing MDS-UPDRS motor scores remained stable with no clinically meaningful progression in 12 evaluable participants. The company also announced plans to submit a new Phase 2 protocol to the FDA in the coming weeks and initiate the trial in 1Q27. This follows the 8-K filed earlier today and the CFO resignation on September 28, adding clinical momentum amid a going concern warning and limited cash runway. The data supports disease-modifying potential and could attract partnership interest, but the company's financial constraints remain a key risk. Watch for the FDA protocol submission and any partnership announcements in the near term.
At the time of this announcement, GANX was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.9M. The 52-week trading range was $1.53 to $4.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.